To evaluate the safety, tolerability and the amount of MK-6482 in your blood when given as tablets with different amounts of the crystalline form of the drug. MK-6482 is intended to treat renal cell carcinoma
During Study 2035, participants will receive the investigative treatment via an oral dose pill of MK-6482.
There is one screening appointment before the overnight stay, and a COVID swab test. There is one follow-up visit required. Compensation for study participation will be provided for time and travel of up to $5,075.
This study has been approved by an independent ethics committee.
Call Lindsay at 651-368-3360 or email her at lindsayd@nucleusnetwork.com to discuss your eligibility today!